Cargando…

A nomogram for the prediction of the survival of patients with advanced non‐small cell lung cancer and interstitial lung disease

BACKGROUND: Lung cancer is frequently accompanied by interstitial lung disease (ILD), and the overall survival (OS) of patients with these comorbidities is poor. Thus, we developed a nomogram for the prediction of the OS of patients with advanced non‐small cell lung cancer (NSCLC) and ILD. PATIENTS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiu, Weigang, Zheng, Jincheng, Zhou, Yuwen, Du, He, Li, Jiayu, Li, Wei, Zhou, Fei, Zhou, Caicun, Wu, Fengying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242331/ https://www.ncbi.nlm.nih.gov/pubmed/36999934 http://dx.doi.org/10.1002/cam4.5852

Ejemplares similares

PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Sun, Chenglong, et al.
Publicado: (2020)

Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer
por: Shi, Jinpeng, et al.
Publicado: (2023)

Clinical nomogram assisting in discrimination of juvenile dermatomyositis-associated interstitial lung disease
por: Hu, Minfei, et al.
Publicado: (2023)

Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
por: Li, Wei, et al.
Publicado: (2014)

The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
por: Zhou, Fei, et al.
Publicado: (2013)

Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer
por: HU, QIONG, et al.
Publicado: (2012)

Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer
por: Pan, Yingying, et al.
Publicado: (2019)

YAP1 expression is associated with survival and immunosuppression in small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2023)

Synchronous ground‐glass nodules showed limited response to anti‐PD‐1/PD‐L1 therapy in patients with advanced lung adenocarcinoma
por: Wu, Fengying, et al.
Publicado: (2020)

Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer
por: Wu, Fengying, et al.
Publicado: (2021)

Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure
por: Zhou, Juan, et al.
Publicado: (2019)

Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
por: Jia, Yijun, et al.
Publicado: (2020)

Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
por: Qiao, Meng, et al.
Publicado: (2021)

MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type
por: Li, Jiayu, et al.
Publicado: (2014)

Non‐small cell lung cancer in China
por: Chen, Peixin, et al.
Publicado: (2022)

Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer
por: Li, Xuefei, et al.
Publicado: (2017)

Development and validation of two prognostic nomograms for predicting survival in patients with non-small cell and small cell lung cancer
por: Xiao, Hai-Fan, et al.
Publicado: (2017)

Fibronectin promotes tumor angiogenesis and progression of non-small-cell lung cancer by elevating WISP3 expression via FAK/MAPK/ HIF-1α axis and activating wnt signaling pathway
por: Zhou, Fei, et al.
Publicado: (2023)

Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
por: Zhou, Qian, et al.
Publicado: (2023)

The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Wang, Haowei, et al.
Publicado: (2021)

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients
por: Li, Xuefei, et al.
Publicado: (2014)

The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
por: Zhao, Chao, et al.
Publicado: (2020)

Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse
por: Guo, Haoyue, et al.
Publicado: (2021)

Anti-Angiogenic Drugs Inhibit Interstitial Lung Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer
por: Wang, Yanning, et al.
Publicado: (2022)

The effects of tislelizumab treatment on the health‐related quality of life of patients with advanced non‐small cell lung cancer
por: Huang, Dingzhi, et al.
Publicado: (2023)

A nomogram for predicting overall survival in patients with resected non-small cell lung cancer treated with chemotherapy
por: Zeng, Yuan, et al.
Publicado: (2021)

Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study
por: Guo, Xiaojin, et al.
Publicado: (2022)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
por: Wang, Yan, et al.
Publicado: (2018)

Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
por: Kato, Motoyasu, et al.
Publicado: (2014)

Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients
por: Zhao, Chao, et al.
Publicado: (2020)

The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection
por: Shi, Jinpeng, et al.
Publicado: (2021)

Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer
por: Xu, Qinghua, et al.
Publicado: (2015)

Combination of Baseline and Variation of Prognostic Nutritional Index Enhances the Survival Predictive Value of Patients With Advanced Non-Small Cell Lung Cancer Treated With Programmed Cell Death Protein 1 Inhibitor
por: Fang, Qiyu, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

Analyses of prognostic factors in cases of non-small cell lung cancer with multiple brain metastases
por: Gong, Xiaomei, et al.
Publicado: (2016)

Immunotherapy in non-small cell lung cancer: advancements and challenges
por: Zhou, Fei, et al.
Publicado: (2021)

A methylation-based nomogram for predicting survival in patients with lung adenocarcinoma
por: Wang, Xuelong, et al.
Publicado: (2021)

Association between Single Nucleotide Polymorphisms (SNPs) and Toxicity of Advanced Non-Small-Cell Lung Cancer Patients Treated with Chemotherapy
por: Zhang, Ling, et al.
Publicado: (2012)

Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis
por: Wen, Yaokai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_67jb1uaob268ajgct4uqt727ic